In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices
- PMID: 15245890
- DOI: 10.1016/j.jconrel.2004.04.011
In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices
Abstract
We have studied the in vitro release kinetics of two important antirestenosis drugs from biodegradable stent matrices. A helical stent incorporating drugs was exposed to buffer, and both degradation-controlled and diffusion-controlled drug releases were observed. New methods for in vitro drug release for both paclitaxel and rapamycin have been developed. The release profile shows a slow diffusion-controlled phase, followed by a more rapid degradation-controlled region. In the early part of the drug release, no burst effect is observed for either drug. This might be significant for paclitaxel administration, where cardiotoxicity has been sometimes of concern. By suitable polymer/drug formulations, it is possible to develop controlled release stent matrices that can exhibit a variety of release profiles. These release profiles may have relevance to antirestenotic effects and to local or systemic toxic effects.
Similar articles
-
Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents.Colloids Surf B Biointerfaces. 2009 Oct 15;73(2):199-206. doi: 10.1016/j.colsurfb.2009.05.016. Epub 2009 May 27. Colloids Surf B Biointerfaces. 2009. PMID: 19541460
-
Release profiles in drug-eluting stents: issues and uncertainties.J Control Release. 2007 Jul 31;120(3):149-60. doi: 10.1016/j.jconrel.2007.04.022. Epub 2007 May 22. J Control Release. 2007. PMID: 17582635 Review.
-
Evaluation of acrylate-based block copolymers prepared by atom transfer radical polymerization as matrices for paclitaxel delivery from coronary stents.Biomacromolecules. 2005 Nov-Dec;6(6):3410-8. doi: 10.1021/bm050464v. Biomacromolecules. 2005. PMID: 16283773
-
Drug-eluting stents.Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Arch Cardiol Mex. 2006. PMID: 17091802 Review.
-
Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.Circulation. 2006 Jan 17;113(2):273-9. doi: 10.1161/CIRCULATIONAHA.105.575977. Epub 2006 Jan 3. Circulation. 2006. PMID: 16391155 Clinical Trial.
Cited by
-
Degree of bioresorbable vascular scaffold expansion modulates loss of essential function.Acta Biomater. 2015 Oct;26:195-204. doi: 10.1016/j.actbio.2015.08.009. Epub 2015 Aug 12. Acta Biomater. 2015. PMID: 26277377 Free PMC article.
-
Translation in cardiovascular stents and occluders: From biostable to fully degradable.Bioeng Transl Med. 2017 Jul 19;2(2):156-169. doi: 10.1002/btm2.10066. eCollection 2017 Jun. Bioeng Transl Med. 2017. PMID: 29313029 Free PMC article. Review.
-
Novel bioerodable eluting-spacers for radiotherapy applications with in situ dose painting.Br J Radiol. 2019 Jun;92(1098):20180745. doi: 10.1259/bjr.20180745. Epub 2019 May 14. Br J Radiol. 2019. PMID: 31084497 Free PMC article.
-
Modeling gold nanoparticle-eluting spacer degradation during brachytherapy application with in situ dose painting.Br J Radiol. 2017 Jun;90(1074):20170069. doi: 10.1259/bjr.20170069. Epub 2017 May 4. Br J Radiol. 2017. PMID: 28383280 Free PMC article.
-
In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation.J Bioequivalence Bioavailab. 2009 May 9;1:3-12. doi: 10.4172/jbb.1000002. J Bioequivalence Bioavailab. 2009. PMID: 20190878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources